【Asset for Licensing】Orally bioavailable selective WRN small-molecule inhibitor

Asset: Orally bioavailable selective WRN small-molecule inhibitor
Development Stage: Clinical stage
Indication: Multiple solid tumors
Key Asset Highlights:
（1）Exhibits high selectivity and potent inhibitory activity against WRN helicase, a critical synthetic lethal target for microsatellite instability-high (MSI-H) tumors with unique epigenetic and DNA repair regulatory functions.
（2）Delivers superior anti-tumor potency in refractory solid tumor models, demonstrating distinct differentiation from conventional chemotherapy and immune checkpoint therapies.
（3）Possesses favorable oral pharmacokinetic properties and a well-established safety window, enabling convenient outpatient oral administration and sustainable long-term clinical treatment.
（4）Protected by a comprehensive and robust intellectual property portfolio, ensuring stable and exclusive global development and commercialization rights for WRN-targeted solid tumor therapy.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.